Viz.ai and Erlanger Health System Partner to Bring Innovative Artificial Intelligence to Stroke Care

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180725005405/en/

Viz.ai and Erlanger Health System Partner to Bring Innovative Artificial Intelligence to Stroke Care (Photo: Business Wire)

Erlanger has partnered to use Viz LVO, a cloud-based artificial intelligence system that can automatically analyze CT scans for suspected large vessel occlusions (LVOs), along with Viz CTP into its clinical workflow. After a patient undergoes a CT scan, Viz LVO alerts the stroke specialist of a suspected LVO, allowing the specialist to proactively review the images on their smartphone. Analysis, performed by deep learning algorithms, is automatic and occurs in minutes. Viz LVO is the only stroke triage software to receive FDA clearance.

Erlanger anticipates that Viz LVO will improve the stroke pathway in one of the largest and busiest stroke programs in the United States by reducing treatment times and increasing patient access to potentially life-savings therapies such as mechanical thrombectomy. Earlier diagnosis and faster transfer to an interventional stroke center for advanced stroke treatment has the potential to improve patient outcomes.

“There is no more time-sensitive treatment in all of medicine than that required when responding to stroke,” said Dr. Thomas G. Devlin, Executive Medical Director, University of Tennessee Erlanger Neurology and Co-Director of the Erlanger Southwest Regional Stroke Center. “Viz LVO combines ground breaking AI with frictionless communication. It provides the resources to help shave off critical minutes, even hours, in the triage, diagnosis and treatment of stroke and allows stroke specialists to be proactive rather than reactive. Viz LVO facilitates fast and accurate detection and referral of large vessel occlusion strokes enabling better collaboration between the stroke teams at comprehensive and referral hospitals.”

Erlanger Health System will roll out Viz LVO across the Erlanger network, followed by expansion to the rest of their referral network.

“Viz.ai transforms stroke care not only for our patients, but for the entire region,” said Joseph Winick, FACHE, Lead Executive, Erlanger Innovation Center at Erlanger Health System. “Viz LVO allows us to deliver the right care in the right place, potentially improving outcomes, while lowering cost. Viz LVO provides an AI platform to drive ROI”.

About Stroke

Stroke is a leading cause of permanent disability, death and healthcare costs globally. According to the American Heart Association/American Stroke Association (AHA/ASA), stroke is the fifth leading cause of death in the U.S. and a leading cause of disability. When a stroke occurs, and the flow of oxygen-rich blood to a portion of the brain is blocked, two million brain cells die every minute; in the case of stroke, “time is brain.”

About Viz.ai, Inc.

Viz.ai, Inc is emerging as the leader in applied artificial intelligence in healthcare. Their mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment and improve access to care.

Their flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat.

In February 2018, the U.S. Food and Drug Administration (FDA) granted a De Novo clearance for Viz LVO, the first-ever computer-aided triage and notification platform. Most recently, Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral image analysis.

Viz.ai are located in San Francisco and Tel Aviv and backed by leading Silicon Valley investors, including Kleiner Perkins, Google Ventures, Innovation Endeavors and DHVC.

To find out more, visit http://www.Viz.ai, follow us on Twitter or find us on LinkedIn.

Viz LVO and Viz CTP indications of use can be found at https://www.viz.ai/indications-for-use/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180725005405/en/